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Abstract
Administration of facultative anaerobic bacteria such as Salmonella enterica serovar
Typhimurium as anticancer treatment holds a great therapeutic potential. Here, we
tested different routes of application of S. typhimurium with regard to tumor
colonization and therapeutic efficacy. No differences between intravenous and
intraperitoneal infection were observed, often leading to a complete tumor clearance.
In contrast, after oral application, tumor colonizationwas inefficient and delayed. No
therapeutic effect was observed under such conditions. We also showed that tumor
invasion and colonization were independent of functional Salmonella pathogenicity
island (SPI) 1 and SPI 2. Furthermore, tumor invasion and colonization did not
require bacterial motility or chemotactic responsiveness. The distribution of the
bacteria within the tumor was independent of such functions.
Introduction
For almost 200 years it has been known that bacteria have
the ability to colonize solid tumors and induce tumor
shrinkage. Despite some success, the employment of bacter-
ia or bacterial components was only anecdotal due to the
severe side effects of such therapies (Coley, 1893). However,
the dramatic improvements of molecular genetics of bacter-
ia within the last decades have made feasible the application
of appropriately attenuated pathogenic bacteria to cancer
patients. Consequently, this possibility is at present under
intense investigation (Leschner & Weiss, 2010).
Many obligate and facultative anaerobic bacteria are able
to colonize solid tumors, among them Salmonella enterica
serovar Typhimurium. Thus far, S. typhimurium has been
shown to exert strong therapeutic effects on tumors upon
intravenous administration (Zhao et al., 2005). In the
tumor, Salmonella mainly resides in the inner necrotic part
of neoplasias (Pawelek et al., 1997a; Avogadri et al., 2005;
Westphal et al., 2008). Obviously, conditions like low oxygen
tension, protection from phagocytic immune cells and
probably also the high nutrient supply from dying tumor
cells support the survival and proliferation of the bacteria
within the tumor. In contrast, a strain, auxotrophic for
leucine and arginine, targets tumor tissue specifically, in-
cluding the complete viable malignant tissue (Zhao et al.,
2006; Hayashi et al., 2009; Kimura et al., 2010).
Normally, S. typhimurium uses an intestinal port of entry
via ingestion of contaminated food and water (Jones et al.,
1992). After breaching the epithelial barrier, the bacteria
colonize Peyer’s patches, mesenteric lymph nodes and sub-
sequently spread to the deep organs spleen and liver (Finlay
& Brumell, 2000; Barthel et al., 2003). Different components
of Salmonella are involved in the invasion and infection
process. For instance, the cell envelope component lipopo-
lysaccharide is important for survival in the host (Gunn,
2008). In addition, particular virulence factors are found,
most of which are encoded in particular genetic elements
including Salmonella pathogenicity islands 1 and 2 (SPI 1
and SPI 2). Their prominent features are the so-called
type three secretion systems, which allow the injection of
bacterial effector proteins into the cytosol of the host cell
(Waterman & Holden, 2003; Stecher et al., 2004; Bueno
et al., 2005; Jones et al., 2007). Here, SPI 1 is important for
the invasion of host epithelial cells (Main-Hester et al.,
2008), while SPI 2 is essential for intracellular survival in
the Salmonella-containing vacuoles after invasion (Cirillo
et al., 1998).
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For successful Salmonella-mediated tumor therapy, bac-
teria are generally administered intravenously. However,
there are some reports described an application via the
natural oral route that successfully inhibited tumor growth
(Medina et al., 1999; Panthel et al., 2008; Fest et al., 2009).
Nevertheless, comparison of the different requirements of
bacterial administration for tumor therapy has only been
approached to a small extent.
In addition, the tumor invasion process of the systemi-
cally applied Salmonella is not yet clear, although this
knowledge will be required for optimization of the bacterial
targeting of cancerous tissue. An active scenario that in-
volves several bacterial chemotactic systems has been sug-
gested using cylindroids of tumor cells in vitro (Forbes et al.,
2003). From our studies, we suggest a rather passive
mechanism by which the cytokines that are elicited after
intravenous application of the Salmonella open the blood
vessels in the tumors and allow the entry of the bacteria.
Similar results published by the Szalay group also support a
passive tumor mechanism (Stritzker et al., 2010). However,
both scenarios are not mutually exclusive and need to be
investigated in more detail.
In addition, a controversy exists with regard to the
involvement of SPI 1 or SPI 2 in tumor targeting and
survival. As the bacteria are normally applied intravenously,
factors encoded in SPI 1 should not be necessary. However,
products of SPI 2 were described to be essential for tumor
targeting (Pawelek et al., 2002). This would suggest that
bacteria might exist intracellularly in the tumors. Thus far,
when examining infected tumors we hardly ever found
bacteria residing within cells. Therefore, we wanted to
re-examine the requirement of intact SPI 1 and SPI 2 for
systemic tumor therapy.
Materials and methods
Bacterial strains and growth conditions
Salmonella typhimurium strain SL7207 (DhisG, DaroA) was
kindly provided by Bruce Stocker (Hoiseth & Stocker, 1981).
For in vivo imaging, lux was integrated into the chromo-
some (Loessner et al., 2007). Salmonella typhimurium
SL1344 and the mutants DcheY, DfliGHI, DinvG, DphoP,
DsseD, DssrB, DaroA and DpurA (Table 1) were provided by
Wolf-Dietrich Hardt (Stecher et al., 2004a; Hapfelmeier
et al., 2005). The strains were prepared via deletion of the
described genes (Datsenko & Wanner, 2000). The bacteria
were grown on Luria–Bertani (LB) agar plates supplemented
with 30 mgmL1 streptomycin at 37 1C.
Cell lines and animals
Six-week-old female BALB/c mice were purchased from
Janvier (France). CT26 colon carcinoma cells (ATCC CRL-
2638) were grown as monolayers in IMDM medium (Gibco
BRL, Germany) supplemented with 10%v/v heat-inacti-
vated fetal calf serum (Integro, the Netherlands),
250 mmol L1 b-mercaptoethanol (Serva) and 1% v/v peni-
cillin/streptomycin (Sigma, Germany).
Infection of tumor-bearing mice and recovery of
bacteria from tissue
Six-week-old female BALB/c mice were subcutaneously
injected with 5 105 CT26 cells in the abdomen. When the
tumors had reached a size of 5–8mm in diameter, mice were
injected intravenously or intraperitoneally with 5 106 CFU
of S. typhimurium in phosphate-buffered saline (PBS). For
oral infection 5 108 CFU were used. At different time
points postinfection, mice were sacrificed and tumor, spleen
and liver were removed for further analysis. The organs were
transferred into 1mL (2mL for liver) ice-cold PBS contain-
ing 0.1% v/v Triton X-100. The tissue was homogenized
with a Polytron PT3000 homogenizer. To determine
CFUg1 of organ, homogenates were serial diluted in
PBS and plated on LB plates containing streptomycin
(30 mgmL1).
All animal experiments have been performed with the
permission of the local authorities (LAVES) according to the
Animal Welfare act.
Table 1 Mutant strains of Salmonella typhimurium
SL1344 Affecting Function
DcheY Chemotaxis Regulator of agella rotation; mutants are unable to respond to chemotactic signals
DfliGHI Flagella Assembly of agella structural proteins
DinvG SPI 1 Component of SPI 1 TTSS response regulator of two-component transcriptional regulator
DphoP SPI 1/2 phoP/phoQ
DsseD SPI 2 Translocon protein of SPI 2 TTSS; part of two-component regulatory system ssrA/ssrB
of SPI 2
DssrB SPI 2 TTSS
DaroA Metabolism Biosynthesis of aromatic amino acids
DpurA Metabolism Biosynthesis of adenine and guanine
TTSS, type three secretion systems.
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Tumor studies
To follow the development of tumor size, 6-week-old female
BALB/c mice were injected subcutaneously with 5 105
CT26 cells. As soon as small tumors become visible, tumor
size was monitored every other day using calipers. The
volume of the tumor was calculated using the formula:
V= 4/3 p (hw2)/8, where h is the height and w the
width. It was assumed that the depth and width of the tumor
were equal.
In vivo imaging
For the visualization of early time points of bacterial
spreading after infection, the IVIS system (Xenogen) was
used. The lux operon was used as reporter system for the
distribution of bacteria. BALB/c mice were infected intrave-
nously, intraperitoneally or orally with SL7207lux and im-
mediately anesthetized using isoflurane for in vivo imaging.
Pictures were taken immediately, 10min, 2 h and 24 h after
infection using a comparable intensity scale.
Histology
Tumors were taken from sacrificed mice and frozen in Tissue-
Tek OCT Compound (Sakura Finetek). Sections of 10mm
were cut using a microtome-cryostat (Cryo-Star HM560V,
Microm). Slides were air dried at room temperature overnight
and fixed in  20 1C acetone for 3min. Slides were rehydrated
in PBS and blocked with 1mgmL1 FcR blocker (rat-a-mouse
CD16/CD32). Staining was done with the following reagents:
polyclonal rabbit anti-S. typhimurium (US Biological), poly-
clonal goat anti-rabbit Alexa 488 (Sigma-Aldrich), Phalloidin
Alexa 594 (Molecular Probes) and DRAQ5 (Biostatus). After-
wards, the slides were washed and dried and covered with
Neomount (Merck) and coverslips. The samples were ana-
lyzed using a laser scanning confocal microscope (LSM 510
META, Zeiss). Images were processed with LSM5 IMAGE BROWSER
(Zeiss) and ADOBE PHOTOSHOP 7.0.
Results
Comparison of application routes for bacterial
tumor colonization
The natural port of entry for S. typhimurium is the intestine.
However, the tumor targeting experiments are usually
carried out via the intravenous route, although some reports
describe oral application. We therefore wanted to system-
atically compare the various infection routes for their
efficiency with respect to tumor colonization. Within these
experiments we employed SL1344DaroA. This strain is
auxotrophic for histidine (Wray & Sojka, 1978) as well as
aromatic amino acids. Mice were injected subcutaneously
with the colon carcinoma cell line CT26. After the tumor
had reached a size of 5mm in diameter, the tumor-bearing
mice were infected by different routes with the attenuated
S. typhimurium strain. After intravenous and intraperitoneal
infection, mice were sacrificed on days 1, 3, 10 and 17 after
infection and the number of bacteria was determined for
tumor, spleen and liver (Fig. 1). As expected, tumors were
preferentially colonized and showed up to 100 times higher
colonization than spleen and liver. Bacterial tumor loads
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Fig. 1. Colonization of tumor, spleen and liver
after intravenous, intraperitoneal and oral applica-
tion of SL1344DaroA. Bars represent the mean of
five mice per group SD.
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decreased slightly till day 17. In contrast, in normal target
organs, spleen and liver bacteria increased till day 3 and then
slowly subsided.
Because of delayed tissue colonization in the case of oral
infection, mice were sacrificed at days 2, 6, 11, 15 and 22
postinfection and tissues were plated. Bacteria could only be
detected at day 11. The tumors were preferentially colonized
but to a much lower degree than after systemic application.
In general, the number of bacteria in the tissues was about
100 times lower compared with intravenous or intraperito-
neal infection.
The development of tumor size was also monitored under
these conditions. After intravenous and intraperitoneal
infection, a dramatic reduction of tumor volume was
observed (Fig. 2). The tumor colonization of SL1344DaroA
was reflected in a complete clearance of tumors. Consis-
tently, after oral infection, which had led to a transient low
colonization of the tumor, no reduction of tumor size was
detectable.
The colonization of organs and tumor was also followed via
in vivo imaging (Fig. 3). Recombinant bacteria of the strain
SL7207lux, carrying an integrated lux operon, were used to
visualize bacterial distribution during early infection. Bacteria
of the strain SL7207 contain the same attenuations and were
shown to behave comparable to SL1344DaroA. The amount of
CFU was lower in different organs but the pattern of infection
and survival of mice was comparable (Supporting Informa-
tion, Figs S1 and S2). After intravenous infection, bacteria
immediately spread out through the whole organism. A strong
signal from liver and spleen was already detectable after
10min. After 24h, an additional very strong signal from the
tumor appeared. After intraperitoneal infection, the signal
from liver and spleen was not that obvious due to a long-
lasting strong signal from the peritoneum. Nevertheless, after
24h the tumor showed strong bioluminescence.
In contrast, a 100 times weaker signal was observed
directly after oral infection. Bacteria could be detected in
the gut up to a few hours after infection. After 24 h the signal
was too weak for detection.
Tumor colonization by metabolically attenuated
mutants
The employment of SL1344 allowed the comparison of wild-
type (WT) bacteria with mutant bacteria (Table 1) that were
mutated in metabolic pathways, commonly used for attenua-
tion of vaccine carrier strains (Fig. 4). Therefore, we compared
WT bacteria with DaroA and DpurA, which are unable to
synthesize either aromatic amino acids or purines such as
adenine and guanine. Interestingly, at 12-h postinfection, WT
bacteria were able to colonize tumors as well as spleen to a
higher degree the attenuated strains could. By 24 h, bacteria of
the DaroA strain had colonized tumor and spleen to the same
extent as the WT. The DpurA strain, however, never grew to
such numbers and appeared to be overattenuated. After 2 days
all mice had to be killed due to a severe health status after
intravenous infection with WT SL1344, while most of the
mice infected with the mutant strains recovered from the side
effects of the infection.
Tumor colonization by mutants in SPI 1 and SPI 2
The SPI 1 and SPI 2 are essential for bacterial invasion and
intracellular survival under natural conditions, respectively.
However, in the case of tumor targeting such functions
might be dispensable, as the Salmonella are applied intrave-
nously and appear to reside extracellularly in the tumor
tissue (Loessner et al., 2007a). We therefore tested the
bacterial mutants DinvG and DphoP. These are essential for
the function of SPI 1, DphoP is influencing SPI 2, or DsseD
and DssrB mutants, which abolish the function of SPI 2, for
tumor invasion and colonization. The efficiency of tumor
invasion and survival was obviously not affected by such
mutations (Fig. 4). The mutants invaded the tumor even
slightly better than the WT bacteria as seen at 12-h
postinfection. By 24 h, no difference between bacterial
counts was observable anymore. Thus, virulence factors of
S. typhimurium encoded in SPI 1 and SPI 2 are not essential
for tumor colonization under our conditions.
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Fig. 2. Therapeutic effect of the colonization of tumor-bearing mice by
SL1344DaroA. The infection was carried out 9 days after the administra-
tion of tumor cells and the development is given as percent of tumor size
at day 5. The values shown represent the mean values of five mice per
group SD.
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Fig. 4. Colonization of tumor-bearing mice by mutants of SL1344 12 and 24 h after intravenous infection. Tumor and spleen were tested for the
number of bacteria per gram of tissue. Bars represent the mean value of five mice per group SD. Statistical significance, calculated via Student’s t-test,
is indicated by asterisks: Po 0.05; Po 0.01.
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Fig. 3. Colonization of tumor-bearing mice infected with SL7207lux, carrying chromosomally integrated lux, after intravenous, intraperitoneal or oral
application. Note that the scale is different for intravenous/intraperitoneal and oral infection. Positions of tumors are indicated by black arrows.
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Tumor colonization by immobile variants and
variants with chemotaxis defects
Conflicting ideas exist as to how bacteria enter the tumor
tissue. An active process was suggested that required moti-
lity and chemotaxis by the bacteria (Kasinskas & Forbes,
2006, 2007a). These experiments were carried out in vitro
using tumor cell cylindroids. Hence, we wanted to test the
requirement of motility and chemotaxis under our condi-
tions in vivo. Two variant strains were tested: mutant
DfliGHI is immobile due to an inability to assemble flagella
and DcheY is unable to respond to chemotactic gradients, as
it can no longer regulate the rotation of the flagella.
Importantly, both mutant strains invaded the tumors
slightly better than the WT bacteria, as can be seen at 12-h
postinfection. No difference could be observed at 24 h any-
more, indicating that tumor invasion and colonization are
independent of bacterial motility and chemotaxis. No
difference between such strains could be observed for the
colonization of the spleen at either time point.
Tumor distribution of nonmotile variant
bacteria
Under our conditions, tumor-colonizing Salmonella reside
in the necrotic areas and in the areas between the necrotic
and the viable region, where high numbers of host neutro-
phils are normally also found (Rosenberg et al., 2002;
Westphal et al., 2008a). It is possible that the deletion of the
motile or chemotactic capabilities of the variant strains
might influence their distribution in the tumor. Therefore,
tumors colonized by WT, DcheY or DfliGHI bacteria were
analyzed by immunohistology 24-h postinfection. Bacteria
of the different strains were similarly distributed within the
tumor (Fig. 5). All of them colonized the necrotic areas and
accumulated to some extent in the interface between necro-
tic and viable regions. Thus, motility and chemotaxis do not
appear to be required for tumor invasion and colonization
under our conditions.
Discussion
In industrialized countries, cancer is the second most
frequent cause of death, with an increasing incidence. This
is due to the improved life expectancy of the human
population, as cancer is essentially a disease of old age. In
the face of these facts, the development of novel therapies or
intervention strategies against this devastating disease is
an obligatory task for current biomedical research. Despite
the drawbacks of the first clinical trials (Toso et al., 2002),
the employment of bacteria for the treatment of solid
tumors holds great promises. However, it also became clear
that the understanding of the invasion and colonization
process is essential for a further development of efficacious
strains that can be safely administered to tumor patients.
We investigated the role of some bacterial properties in
tumor invasion and colonization, for which conflicting ideas
exist.
Tumor-targeting bacteria are usually applied systemically.
However, a few reports describe the successful application
via the oral route. Obviously, an oral delivery of therapeutic
bacteria would be advantageous as it would not require any
special equipment or any particular skills for delivery. In
addition, the risk of an over-reaction of the immune system
of the patient would be reduced. However, comparison of
the different routes of application revealed that under our
conditions, systemic administration of the bacteria is much
superior to the oral route. Oral application of SL1344DaroA
only led to a transient colonization of the tumors late after
infection. In contrast, systemic application of bacteria led to
an immediate and robust colonization of the tumor. In
accordance, tumor growth was unaltered when the bacteria
were applied orally, whereas systemic application led to a
strong shrinkage of the tumors and resulted in complete
clearance. Thus, Salmonella when applied orally are able to
reach the tumor tissue but their present therapeutic cap-
abilities render the effects negligible. Nevertheless, appro-
priately engineered strains might eventually allow oral
application for therapeutic purposes.
During these experiments, we noticed that the therapeu-
tic effect was very much dependent on the size of the tumor.
Our standard conditions, to apply the bacteria when the
tumor had reached 0.5–0.8 cm in diameter, allow complete
tumor clearance by the systemically applied Salmonella. In
contrast, less therapeutic efficacy was noticed when the
tumor had reached larger sizes. This might be one of the
reasons why the bacteria after oral application to tumors
0.5 cm in diameter had no effect on tumor growth. Despite
the lower number of colonizing bacteria, a retardation of
tumor growth was expected. However, by the time the orally
applied bacteria reached the tumor it might have been larger
than the critical size for a therapeutic effect.
The mutant strains employed in this study were generated
on the SL1344 genetic background, but for in vivo imaging
of early time points of infection, SL7207lux was used. The
colonization pattern and therapeutic effect on tumor-bear-
ing mice of SL1344DaroA and SL7207 were compared (Figs
S1 and S2). Only slight differences could be observed.
SL7207 colonized various target tissues less efficiently com-
pared with SL1344DaroA. Both strains also differed slightly
in their capacity to induce tumor shrinkage. Whereas
infection with SL1344DaroA induced complete tumor clear-
ance, treatment with SL7207 only eliminated of three of five
tumors. This might be due to differences in the genetic
make-up of the two strains. Nevertheless, the numbers of
bacteria during colonization and especially the kinetics were
comparable.
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Metabolic attenuation in the purine synthesis pathway,
like DpurI, is often used in studies concerning tumor
targeting of Salmonella (Pawelek et al., 1997; Clairmont
et al., 2000). Such strains usually exhibit good performance.
In contrast, the SL1344DpurA, used in our study, appeared
overattenuated.
Under our conditions, we found that Salmonella usually
resided extracellularly after systemic application. This sug-
gested that proteins encoded in the SPI 1 and SPI 2 are not
essential for tumor invasion and colonization. This was
indeed the case. Mutants, in which essential functions of
SPI 1 or SPI 2 were deleted, were efficient tumor colonizers.
Thus, the original report that SPI 2 functions are required
for tumor colonization (Pawelek et al., 2002a) could not be
confirmed. Instead of our CT26 colon carcinoma model,
those previous experiments were carried out in a melanoma
model, in which the bacteria might behave in another way.
Different strain backgrounds were also used and might
explain the different experimental outcomes.
Similarly, an active process was suggested from in vitro
data for tumor invasion (Kasinskas & Forbes, 2007b). This
would require motility and chemotactic responsiveness of
the bacteria. However, in our system, variant Salmonella that
do not have such properties invaded and colonized the
tumors just as efficiently as bacteria exhibiting these proper-
ties. Therefore, we feel that our original hypothesis is
correct, namely, that Salmonella after systemic application
via induction of tumor necrosis factor-a and other cytokines
creates a tumor microenvironment in which the bacteria are
passively flushed in (Leschner et al., 2009). Even the
distribution of the Salmonella within the tumor is indepen-
dent of motility and chemotactic responsiveness. To
×10 ×40
WT
100 µm
cheY
100 µm
fliGHI
100 µm
Fig. 5. Immune histology of tumors colonized
by WT SL1344, immobile mutants (DfliGHI) or a
mutant strain, unable to react to chemotactic
gradients (DcheY). Cryosections of 10 mm
were stained for nuclei (blue), actin (red) and
Salmonella typhimurium (green). Confocal
images show overviews (10) and 40
magnifications of the area in boxes.
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generalize these findings, more and independent tumor
systems will have to be studied.
In conclusion, we have tested several properties of tumor-
targeting bacteria. Our results will help to better understand
the tumor invasion and colonization process for this novel
and highly potential therapeutic strategy.
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